NAMI HelpLine

Search results for: 大灰狼远控教程【免杀网站537v点Com】✔️免杀远控✔️安卓远控·免杀包月·肉鸡批发免杀远控2022·HgDcwa

Canadian Study Finds Safety and Efficacy of Take-Home Buprenorphine/Naloxone Treatment Comparable to Supervised Methadone Treatment for Opioid Use Disorder

Individuals with opioid use disorder (OUD) are often prescribed treatment with methadone, which requires travel to specialized facilities and strict supervision. Recent findings from a randomized controlled trial suggest treatment with buprenorphine/naloxone that can be taken from home may produce similar results with increased flexibility. Patients in the buprenorphine/naloxone group were shown to have improved outcomes in opioid-free urine drug screens compared to those in the control group treated with methadone. Both groups had comparable rates of retention and adverse events.While the findings are promising, further research is needed to develop and evaluate accessible options for treating OUD. To learn more, see the study in the American Journal of Psychiatry.

Brain Stimulation Shown to Affect How Brain Processes Stimuli, Potential to Aid in Stress-Related Disorders

New research suggests that noninvasive vagus nerve stimulation (nVNS), a form of brain stimulation therapy, may help train the brain to more appropriately respond to threats. Researchers conducted a randomized controlled trial among participants without mental health conditions to measure their reaction time and response levels to images. Participants who received nVNS had quicker reaction times overall, increased responsivity to negative images, and decreased responsivity to positive images. In other words, participants’ “fight or flight” response was efficient and appropriate based on the stimulus they were viewing. Future research should focus on testing nVNS in individuals with mental health conditions, particularly those related to stress and threat perception, such as PTSD and anxiety. To learn more, see the study in Brain Stimulation.    

 

ACEs During COVID-19 Pandemic Associated with Poor Mental Health Outcomes Among High School Students

Adverse childhood experiences (ACEs) are potentially traumatic events that occur during childhood and can negatively impact mental health and well-being into adulthood. Recent data from the 2021 Adolescent Behaviors and Experiences Survey (ABES) showed that nearly three-quarters (73%) of U.S. high school students reported at least one ACE during the COVID-19 pandemic. Students with four or more ACEs were about four times more likely to have poor current mental health and 25 times more likely to have past-year suicide attempts compared to those without any ACEs. Identifying vulnerable youth early and providing them with trauma-informed care can help address the mental health needs brought on by ACEs and the COVID-19 pandemic. To learn more, see the report from the CDC.
 

Access to Gender-Affirming Hormone Therapy Associated with Better Mental Health Outcomes Among Transgender Adults

Transgender individuals often face significant mental health challenges, including a higher risk of suicide compared to their cisgender peers. In a recent analysis of data from the 2015 U.S. Transgender Survey, researchers explored the link between receiving gender-affirming hormone therapy (GAH) in adolescence or adulthood and future mental health outcomes. Among adults who indicated that they had ever desired GAH, those who had received it at any point in their life were less likely to report suicidal behavior in the past year or severe psychological distress in the past month. Further, those who received GAH in adolescence (age 14-17) experienced better mental health outcomes than those who received GAH in adulthood. To learn more, see the study in PLOS One.

Letter to HHS Secretary on COVID-19

Letter to HHS Acting Secretary Cochran, expressing thanks for the recent letter to Governors stating the public health emergency (PHE) declaration will likely remain in place throughout 2021.

Letter to Biden Administration on COVID19

Letter to HHS Secretary Becerra and Administrator Brooks-LaSure, urging the Administration to do more to expand access to COVID-19 tests and vaccines for vulnerable populations.

Letter to the Biden Administration on Health Coverage

Letter to HHS Secretary Becerra, IRS Commissioner Rettig, CMS Administrator Brooks-LaSure, and DOL Acting Assistant Secretary Khawar asking that the agencies issue new regulations as soon as possible limiting the sale and availability of short-term, limited-duration (“STLD”) health insurance.

NAMI HelpLine is available M-F, 10 a.m. – 10 p.m. ET. Call 800-950-6264,
text “NAMI” to 62640, or email. In a crisis, call or text 988 (24/7).